Clearpoint Neuro (CLPT) Investor Presentation - Slideshow

Company Overview - ClearPoint Neuro operates as both a biologics & drug delivery company with a potential market exceeding $1 billion, experiencing 109% growth in 2020 despite COVID-19 [3] - It also functions as a medical device company with an existing market opportunity of over $500 million, anticipating the launch of 5+ new products within the next 2 years [3] - The company's key products are supported by a "razor/razorblade" model, with over 85% of revenue derived from single-use disposables and services [5] Technology and Platform - ClearPoint Neuro's platform leverages live MR imaging for real-time guidance and confirmation with sub-millimetric accuracy [7] - The ClearPoint 'Maestro' Brain Model, jointly developed with Philips, enables point-based correspondence across multiple subjects and serves as the foundation for future navigation tools [9] - The ClearPoint platform is compatible with all major MRI scanner brands, including Siemens, Philips, and IMRIS [13] Market Opportunities and Growth Strategy - The company estimates a $1.5 billion market opportunity in biologics & drug delivery, targeting indications like Glioblastoma, Parkinson's Disease, and Huntington's Disease [17] - In Neuro Navigation (DBS), the total current addressable U S market is $72 million (6,000 cases x $12,000/case), with a 10% growth rate [22] - The total current addressable market for ClearPoint Neuro Laser Therapy is $360 million (20,000 cases x $18,000/case), growing at a rate of 20+% [28] - The company's 4-pillar growth strategy aims for a potential addressable market of over $1 billion by 2025, targeting over 150,000 procedures per year [34] Financial Performance - The company's estimated FY21 revenue is $17.5 million [36] - Procedure volume has grown at a 33%+ CAGR from 2013-2019 [37] - In 2021, Biologics and Drug Delivery revenue is estimated at $5 million, Capital and Software at $7.4 million, and Functional Neurosurgery at $3.6 million [35]